WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Postmarket & security

THE TAPE

Elucid raises $55M Series D with FFR-CT 510(k) under FDA review Enovis to buy eCential Robotics for 155 million euros FDA authorizes Vitestro's Aletta, the first autonomous blood-drawing robot, five months after a $70M Series B Renata Medical raises $25M Series D to scale the Minima pediatric stent FDA opens a docket on how to regulate generative AI devices FDA clears Jupiter Endovascular's Vertex thrombectomy system for pulmonary embolism in 89 days FDA clears Wandercraft's Eve, the first self-balancing exoskeleton for home use Meduloc raises $4M Series B to start alpha launch of its nitinol fracture implant FDA sets FY2027 device user fees: $28,653 for a 510(k), $13,785 to register Elucid raises $55M Series D with FFR-CT 510(k) under FDA review Enovis to buy eCential Robotics for 155 million euros FDA authorizes Vitestro's Aletta, the first autonomous blood-drawing robot, five months after a $70M Series B Renata Medical raises $25M Series D to scale the Minima pediatric stent FDA opens a docket on how to regulate generative AI devices FDA clears Jupiter Endovascular's Vertex thrombectomy system for pulmonary embolism in 89 days FDA clears Wandercraft's Eve, the first self-balancing exoskeleton for home use Meduloc raises $4M Series B to start alpha launch of its nitinol fracture implant FDA sets FY2027 device user fees: $28,653 for a 510(k), $13,785 to register

Series A

Spiro Medical raises $67M Series A for an implantable asthma neuromodulator

MedDevice Startups Staff · Jan 7 · 2 min read · Via Company release (PR Newswire)

Spiro Medical raised $67 million in a Series A announced January 7, 2026. Andera Partners led, with Omega Funds and Sherpa Healthcare Partners co-leading. HSG, Supernova Invest, Northern Light Venture Capital and Hero Inc. participated. Sixty-seven million dollars is a large Series A for a device company that surfaced in 2025.

The Irvine, California company is developing the Pulmonary Neuromodulation System. The implant stimulates targeted spinal nerves to modulate airway reflex pathways. Spiro is aiming at severe uncontrolled asthma: wheeze, chest tightness, shortness of breath and cough. Spiro ran a pilot clinical study in 2025 and says it starts with issued patents and human data. Proceeds go to building a purpose-built implant and the clinical work needed for U.S. approval; a novel implant with no predicate is most likely a PMA path with a randomized trial. Co-founders include Stephen Pyles and Kurt Gehlsen, and Rinda Sama is CEO.

Questions & Answers

How much did Spiro Medical raise in its Series A?

Spiro Medical raised $67 million in a Series A announced January 7, 2026. Andera Partners led, Omega Funds and Sherpa Healthcare Partners co-led, and HSG, Supernova Invest, Northern Light Venture Capital and Hero Inc. participated.

What is the Spiro Medical Pulmonary Neuromodulation System?

It is an implantable neuromodulation system that stimulates targeted spinal nerves to reduce symptoms in severe, uncontrolled asthma. Spiro ran a pilot clinical study in 2025; the device is not yet approved by FDA.

Who leads Spiro Medical?

Rinda Sama is CEO of Spiro Medical, which is based in Irvine, California. Co-founders include Stephen Pyles, Kurt Gehlsen and G. Jay Jiang.

← Back to Fundraising